Recent Analysts’ Ratings Updates for Eli Lilly and Company (LLY)

A number of research firms have changed their ratings and price targets for Eli Lilly and Company (NYSE: LLY):

• 5/1/2024 – Eli Lilly and Company had its price target raised by analysts at JPMorgan Chase & Co. from $850.00 to $900.00. They now have an “overweight” rating on the stock.
• 5/1/2024 – Eli Lilly and Company had its price target raised by analysts at BMO Capital Markets from $900.00 to $1,001.00. They now have an “outperform” rating on the stock.
• 5/1/2024 – Eli Lilly and Company had its price target raised by analysts at Truist Financial Co. from $850.00 to $892.00. They now have a “buy” rating on the stock.
• 4/30/2024 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock, up previously from $815.00.
• 4/15/2024 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $815.00 price target on the stock.
• 4/11/2024 – Eli Lilly and Company had its price target raised by analysts at The Goldman Sachs Group, Inc. from $650.00 to $723.00. They now have a “neutral” rating on the stock.
• 4/3/2024 – Eli Lilly and Company was upgraded by analysts at Erste Group Bank AG from a “hold” rating to a “buy” rating.
• 4/2/2024 – Eli Lilly and Company had its price target raised by analysts at Citigroup Inc. from $675.00 to $895.00. They now have a “buy” rating on the stock.
• 4/1/2024 – Eli Lilly and Company had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $815.00 price target on the stock.
• 3/22/2024 – Eli Lilly and Company had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $850.00 price target on the stock.
• 3/15/2024 – Eli Lilly and Company had its price target raised by analysts at JPMorgan Chase & Co. from $775.00 to $850.00. They now have an “overweight” rating on the stock.
• 3/8/2024 – Eli Lilly and Company was upgraded by analysts at TheStreet from a “c+” rating to a “b” rating.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $18.26 on Thursday, reaching $758.49. 1,584,206 shares of the stock were exchanged, compared to its average volume of 3,049,690. The stock has a market cap of $720.69 billion, a PE ratio of 111.71, a PEG ratio of 1.58 and a beta of 0.37. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a twelve month low of $414.31 and a twelve month high of $800.78. The firm has a fifty day moving average price of $762.03 and a two-hundred day moving average price of $669.96.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the previous year, the business earned $1.62 EPS. The business’s revenue was up 26.0% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 13.5 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Large investors have recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $26,000. Core Wealth Advisors Inc. lifted its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the period. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $27,000. Activest Wealth Management acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $39,000. Finally, Tidemark LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $29,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.